Pacific Biosciences of California Inc (PACB) posted $40.6 million in Q3 2026 revenue, narrowed full-year guidance to $155--$160 million, and reaffirmed a path to cash flow breakeven in 2028.
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing sol...
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Key TakeawaysPacBio shares fell 8% after AI drug-discovery company TychoBio said it will use PacBio’s long-read sequencing on more than 10,000 samples. The deal backs PacBio’s pitch to AI companies, but the announcement gave no dollar value.
PacBio will generate full-length RNA data from more than 10,000 samples, which TychoBio will use to train AI models to design treatments for rare diseases
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio’s drug discovery modelsMENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate genomic and epigenomic analysis for rare disease interpretation, incorporating data from PacBio HiFi sequencing.
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like Illumina. Read why PACB stock is a buy.
Detailed price information for Palo Alto Networks (PANW-Q) from The Globe and Mail including charting and trades.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Detailed price information for RPC Inc (RES-N) from The Globe and Mail including charting and trades.
Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be ava
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
This is the newest page. Registered accounts read further back.